Introduction
============

Sulfur mustard \[bis(2--chloroethyl) sulfide; SM\], also known as mustard gas, was initially used as a vesicant chemical warfare agent during World War I. According to the report of the specialists appointed by the Secretary-General of the United Nations, mustard gas was extensively used by Iraq during the conflict against Iran ([@B1]).

Sardasht, a border town in the northwest of Iran, was exposed to sulfur mustard in 1987 by the Iraqi army. In addition to acute extensive multi-organ problems, there are long-term adverse health effects of exposure to mustard gas ([@B2]--[@B4]).

Despite a fair number of reports on clinical manifestations of SM intoxication, there are few studies on paraclinical and molecular parameters and systemic effects of SM long term after exposure. Therefore, the underlying molecular mechanisms are less known.

Various complaints and clinical presentations of the survived people seeking medical care and review of the literature support such concerns, even though no systematic scientific evidence has been available ([@B5]).

A decline in mean serum--free T4 index (FT4I) and free T3 index was reported less than one month after exposure ([@B6]). Moreover, they explained the time course of serum concentration of thyroid hormones. Free T4 and T3 indices decreased and reverse T3 (rT3) increased in the first week following exposure. Except for an increase in FT4I and a decrease in thyroid--stimulating hormone (TSH) by the third week, serum hormone concentrations remained unchanged until the fifth week after injury. They concluded that exposure to chemical weapons containing SM results in alterations in serum concentrations of thyroid hormones.

There is no study on serum concentrations of thyroid hormones long-term after SM exposure. In this study, the changes of thyroid function parameters 20 years after SM exposure were evaluated.

Materials and Methods
=====================

Study Design and Participants
-----------------------------

This study is a part of a larger historical cohort study conducted in 2007 following 20 years of the exposure to SM, called Sardasht, West Azerbaijan Province, Iran cohort study (SICS), of which the details of the study design and methods have been previously reported ([@B7]).

Briefly, the exposed group were male individuals from Sardasht categorized into two major subgroups based on severity of injuries, just after exposure. SM--exposed patients hospitalized based on the severity of injuries after acute exposure were considered as the hospitalized group (n=169) who had a history of at least one--week admission in hospital, and patients with mild and subclinical problems not hospitalized after acute exposure as the non-hospitalized exposed group (n=203).

Control participants were selected from Rabat, a town near Sardasht, concurrently with the exposed group. Moreover, the control samples included men matched with the study group by age (n=126). The age range covered by the study was 20--60 yr. Both study groups were compared in terms of marital status, level of education, employment, and smoking status.

Ethical approval
----------------

The study was approved by the Ethical Committee of the Board of Research Ethics of Janbazan Medical and Engineering Research Center (JMERC), the Board of Research of the Ministry of Health and Medical Education, and Shahed University. Volunteers who signed an informed consent were recruited.

Serum Preparation
-----------------

Peripheral blood samples were taken in the morning in fasting state using Vacationer tubes (BD Biosciences), 20 years following SM exposure in the exposed group and, alongside, in the control group. After clotting, the sera were separated by a 20 min centrifugation at 2000×g in 4 °C, aliquoted and stored at −80 °C until test.

Measurement of Thyroid Hormones
-------------------------------

T3, T4, and TSH were measured by enzyme-linked immunosorbent assay (ELISA) method (DBC, Canada). Intra- and inter-assay coefficients of variations (CV) were 3.3% and 6.2% for T4, 12.3% and 10.4% for T3, and 3.9% and 7.1% for TSH, respectively.

According to the manufacturer's instructions, the normal range was 0.52--1.85 ng/ml for T3, 4.4--10.8 μg% for T4 and 0.4--6.1μIU/ml for TSH.

Antithyroglobulin (anti--Tg) and anti-thyroid peroxidase (anti--TPO) concentrations were measured by ELISA (Radim, Pomezia, Italy).

The values of anti--TPO, up to 150IU/ml and anti--Tg, up to 75IU/ml were considered normal. The inter- and intra-assay CVs were 7.2% and 6.5%, respectively.

Statistical Analysis
--------------------

Statistical analysis was done using the SPSS (Windows, ver. 16.0, Chicago, IL, USA). Values are given as mean (± SD). Comparison of thyroid factors between study groups was done with ANOVA (Tukey's post hoc). Comparison of the normal range was done with chi-square test. A *P*--value of less than 0.05 was considered statistically significant.

Results
=======

The mean age of the exposed group was 44 ± 11 yr. The result revealed insignificant differences in terms of age, marital status, and smoking status in contrast to significant differences in terms of level of education and, and employment, which were higher among the exposed group ([Table 1](#T1){ref-type="table"}).

###### 

Demographic Characteristics of Study Groups

                                   ***Study Groups***   ***P-valve***   ***Clinical severity at exposure time***                                          
  ---------------- --------------- -------------------- --------------- ------------------------------------------ ------- --------- ------ ------ ------ ------
  Age(yr)          \<40            57                   46.0            126                                        35.3              72     36.9   54     33.3
  40 - 50          35              28.2                 113             31.7                                       0.097   59        30.3   54     33.3   
  \>50             32              25.8                 118             33.1                                               64        32.8   54     33.3   
  Marital status   Not-married     9                    7.6             28                                         8.0     0.866     16     8.4    12     7.6
  Married          110             92.4                 320             92.0                                               174       91.6   146    92.4   
  Education        Lower diploma   93                   78.2            201                                        57.9    \<0.001   98     51.9   103    65.2
  Diploma and up   26              21.8                 146             42.1                                               91        48.1   55     34.8   
  Occupation       Employed        52                   44.1            210                                        60.5    0.002     130    68.8   80     50.6
  Unemployed       66              55.9                 137             39.5                                               59        31.2   78     49.4   
  Smoke            Yes             29                   22.8            84                                         22.6    0.573     48     23.8   36     21.3
  No               98              77.2                 287             77.4                                               154       76.2   133    78.7   

The details of hormonal assessment are presented in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Serum T4 (μg/dL) was 7.95 ± 1.44 (range: 4.4--10.8 μg%) and serum TSH was 1.41 ± 2.06 (range: 0.4--6.1 μIU/ml) in the exposed group. T4 was 8.24 ± 1.78 (range: 4.4--10.8 μg%) and TSH was 1.47 ± 2.19 (range: 0.4--6.1μIU/ml) in the control group.

###### 

Thyroid hormones levels in Sulfur mustard Exposed and control groups

  ***Study Groups***         ***N***     ***Mean***   ***SD***   ***Median***   ***P-value^[1](#TFN1){ref-type="table-fn"}^***   ***P-value^[2](#TFN2){ref-type="table-fn"}^***   
  -------------------------- ----------- ------------ ---------- -------------- ------------------------------------------------ ------------------------------------------------ --
  T3 ng/ml                   Unexposed   127          .80        .25            .82                                                                                               
  Exposed Non Hospitalized   202         .88          .27        .84            0.018                                                                                             
  Exposed Hospitalized       169         .87          .24        .86            0.058                                            0.924                                            
  Exposed                    371         .88          .26        .85            0.005                                                                                             
  T4 micg/dl                 Unexposed   127          8.24       1.78           8.10                                                                                              
  Exposed Non Hospitalized   202         8.02         1.45       8.10           0.395                                                                                             
  Exposed Hospitalized       169         7.88         1.43       8.00           0.109                                            0.665                                            
  Exposed                    371         7.95         1.44       8.00           0.068                                                                                             
  TSH mIU/L                  Unexposed   127          1.47       2.19           1.01                                                                                              
  Exposed Non Hospitalized   202         1.61         2.66       1.10           0.809                                                                                             
  Exposed Hospitalized       169         1.18         .90        .91            0.460                                            0.110                                            
  Exposed                    371         1.41         2.06       1.02           0.805                                                                                             
  T3uptake %                 Unexposed   127          28.50      2.27           29.00                                                                                             
  Exposed Non Hospitalized   202         28.93        2.28       29.00          0.217                                                                                             
  Exposed Hospitalized       169         28.74        2.26       29.00          0.632                                            0.712                                            
  Exposed                    371         28.84        2.27       29.00          0.140                                                                                             
  Tg ng/ml                   Unexposed   121          17.66      41.49          9.40                                                                                              
  Exposed Non Hospitalized   200         56.07        140.22     11.55          0.004                                                                                             
  Exposed Hospitalized       166         31.95        82.22      10.50          0.484                                            0.071                                            
  Exposed                    366         45.13        117.98     11.00          0.012                                                                                             
  anti Tg IU/ml              Unexposed   93           81.64      291.88         21.99                                                                                             
  Exposed Non Hospitalized   134         62.98        141.93     25.32          0.742                                                                                             
  Exposed Hospitalized       98          43.80        91.95      22.05          0.346                                            0.722                                            
  Exposed                    232         54.88        123.44     24.48          0.001                                                                                             
  anti TPO IU/ml             Unexposed   94           36.56      108.20         7.72                                                                                              
  Exposed Non Hospitalized   132         29.22        82.34      6.79           0.815                                                                                             
  Exposed Hospitalized       99          26.16        77.39      7.35           0.697                                            0.964                                            
  Exposed                    231         27.91        80.10      7.20           0.246                                                                                             
  Free T4 Index              Unexposed   127          235.07     53.71          231.40                                                                                            
  Exposed Non Hospitalized   202         231.34       43.46      230.00         0.763                                                                                             
  Exposed Hospitalized       169         226.56       45.66      226.20         0.273                                            0.593                                            
  Exposed                    371         229.16       44.48      229.50         0.222                                                                                             
  Free T3 Index              Unexposed   127          22.90      7.52           22.80                                                                                             
  Exposed Non Hospitalized   202         25.60        8.44       24.38          0.007                                                                                             
  Exposed Hospitalized       169         25.07        7.22       24.32          0.048                                            0.791                                            
  Exposed                    371         25.36        7.90       24.32          0.002                                                                                             

*P*-value^1^: Comparison with Control (ANOVA and t-test) //

*P*-value^2^: Comparison between hospitalize and non-hospitalized (ANOVA Tukey Post hoc) //

TSH= thyroid stimulating hormone; Tg=Thyroglobulin; TPO= Thyroid peroxidase

###### 

Comparison of thyroid hormone levels between study groups according to the normal levels

  ***Variable***           ***Unexposed***   ***Non-Hospitalized***   ***Hospitalized***   ***Exposed***                                                          
  ------------------------ ----------------- ------------------------ -------------------- --------------- ------- ------- ------ ------- ------- ------- ------- -------
  T3 level (0.52 - 1.85)   \< 0.52           15                       11.8                 10              5.0             6      3.6             16      4.3     
  Normal                   111               87.4                     189                  93.6            0.065   162     95.9   0.023   351     94.6    0.010   
  \> 1.85                  1                 .8                       3                    1.5                     1       .6             4       1.1             
  T4 Level (4.4 - 10.8)    \< 4.4            1                        .8                   4               2.0             1      .6              5       1.3     
  Normal                   121               95.3                     193                  95.5            0.528   165     97.6   0.513   358     96.5    0.494   
  \> 10.8                  5                 3.9                      5                    2.5                     3       1.8            8       2.2             
  TSH Level (0.4 - 6.1)    \< 0.4            21                       16.5                 22              10.9            30     17.8            52      14.0    
  Normal                   104               81.9                     175                  86.6            0.300   139     82.2   0.256   314     84.6%   0.767   
  \> 6.1                   2                 1.6                      5                    2.5                     0       .0             5       1.3             
  T3up Level (25 - 38)     \< 25             7                        5.5                  6               3.0             7      4.1             13      3.5     
  Normal                   120               94.5                     196                  97.0            0.249   162     95.9   0.583   358     96.5    0.320   
  \> 38                    0                 .0%                      0                    .0                      0       .0             0       .0              
  anti Tg 50--75           lower 75          82                       88.2                 112             83.6    0.335   91     92.9    0.268   203     87.5    0.868
  75 and up                11                11.8                     22                   16.4                    7       7.1            29      12.5            
  anti TPO 100--150        lower 150         89                       94.7                 126             95.5    0.790   95     96.0    0.674   221     95.7    0.700
  150 and up               5                 5.3                      6                    4.5                     4       4.0            10      4.3             

*P*-value: Comparison with Control (Chi-square test)

TSH= thyroid stimulating hormone; Tg=Thyroglobulin; TPO= Thyroid peroxidase

The mean of T3 concentration was significantly higher in the exposed group (0.88±0.26 nmol/L) compared to the control (0.80 ± 0.25) (*P*\<0.001); however, these values were still within normal clinical range. The levels of TSH, T4, T3 up, anti--Tg and anti--TPO were not significantly different between the exposed and control groups. Regarding two subgroups of exposure (hospitalized and non-hospitalized), the patterns of measured parameters were similar. Thyroglobulin level was higher in the exposed but not hospitalized group (56.07±140.22 μg/L, *P*=0.004), compared to the control group. The free T3 index, calculated from the serum total of T3 and T3 uptake, was significantly elevated in the exposed group similar to the T3 level. The results of this study showed that the ratio of T3 to T4 in the exposed group was significantly higher than the control group (*P*= 0.006) ([Table 4](#T4){ref-type="table"}).

###### 

The ratio of T3 to T4 in study group

  ***Study Groups***   ***N***   ***Mean T3/T4***   ***Standard Deviation***   ***Median T3/T4***   ***P-value***
  -------------------- --------- ------------------ -------------------------- -------------------- ---------------
  Control              127       .0100              .00356                     .0100                0.006
  Exposed              371       .0115              .00577                     .0108                

Discussion
==========

The aim of this study was to determine the circulating levels of thyroid hormones 20 years after SM exposure. The mean concentrations of T4 and TSH in the exposed group were not significantly different from the control group. Whereas serum T3 concentrations and T3/T4 ratio exhibited significant increase in SM-exposed people compared to the control group; however, it was within normal clinical range. Severity of injury had no effect on this hormone level. We also assessed TPO, Tg and anti--Tg. The data showed elevated levels of Tg in the SM--not hospitalized exposed group compared to the control group. However, the level of anti--Tg showed no significant differences between the two groups. Anti--TPO was similar in both groups.

To our knowledge, this is the first report pointing to circulating levels of thyroid hormones, 20 years after SM exposure. So far there has been no study on the long-term effects of SM exposure on these parameters to compare.

Serum concentrations of thyroid hormones were measured in the first, third, and fifth week following injury in the SM--exposed group compared to the control group, in order to evaluate the time course of changes in serum concentrations of thyroid hormones, cortisol, and adrenocorticotropic hormone (ACTH) in patients exposed to chemical weapons containing SM ([@B6]). In the first week after exposure, free T4 and T3 indices decreased and rT3, cortisol, and ACTH increased. Thereafter, serum hormone concentrations remained unchanged until the fifth week after injury, except for an increase in FT4I, a decrease in TSH by the third week, and a steady decline in serum cortisol. In the current study 20 years following exposure to SM, we found significantly higher levels of T3 in the exposed group compared to the control group, whereas, T4 and TSH levels were not statistically significant. This result is in contrast to acute effects of SM exposure, demonstrated in the foregoing study. The time interval of the post-exposure could be reasonable justification for this dissimilar hormone level. However, other undiscovered pathophysiological mechanisms also should be considered.

Since thyroid function tests in the SM--exposed people in the other studies were assessed short term after exposure, there was no comparable data. Anyway, consistent with the short-term findings ([@B6]), no changes were seen in the serum levels of T4 and TSH in our study, 20 years after SM exposure.

The delayed toxic effects of SM were documented in Iranian veterans, focusing on head and neck complications. For the first time, they reported carcinomas of thyroid and nasopharynx in patients with SM exposure ([@B8]).

Despite the decrease in T3 level in most of these reports, different elucidations could interpret the elevation of T3 in our study; one is that more subjects in our control group have lower level of T3 than normal range (11.8% in control and 4.3% in exposed). On the other hand, there are numerous human and animal studies on the variety of chemicals that disrupt thyroid hormone homeostasis. Such differences in T3 and T3/T4 ratio were observed in exposure to contaminant chemicals such as PCBs in fish ([@B9]).

In vertebrates, the main hormone produced by thyroid, prohormone T4, is converted to T3 in peripheral target tissue cells by 5--deiodinase ([@B10]). The differences in T3 and T3/T4 ratio may point to alterations in the peripheral conversion of T4 into T3. Some studies on fish suggested that pesticides and other chemicals may alter 5--deiodinase activity, which can lead to increased T3 and decreased T4 ([@B4]--[@B6], [@B11]--[@B13]). Although there has been no study on the cellular and molecular mechanisms involved in SM-induced thyroid function disorders, there are a large number of studies on endocrine--disrupting chemicals (EDCs).

Numerous mechanisms have been proposed, including changes in the expression of a large number of potential target genes or proteins, altered by EDCs ([@B14]). Activation of EDCs may interfere with thyroid function by interfering with thyroid hormone synthetic pathways, deiodinase functions in peripheral tissues, altering TH turnover, and carrying proteins in the blood ([@B6], [@B8], [@B13], [@B15]--[@B19]).

However, the limitation of this study is that as our subjects were selected from a previous large cohort study, detailed clinical evaluation in view of specific thyroid assessment was not performed. Further insight into the role of SM in the pathogenesis of thyroid requires deep researches on the cellular and molecular mechanisms involved. This would enable both researchers and clinicians to provide more accurate evaluation and therapeutic strategies when dealing with sufferers of SM exposure.

More studies are needed on the alterations in thyroid hormones, their gene expressions, and involved mechanisms in SM exposure to clarify the causes of these alterations.
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